Clinical TrialsSearch results
Number of results: 318
Other
- Randomized Phase III Trial of Irinotecan plus Cisplatin vs. bi-weekly Irinotecan after S-1 failure for Patients with Advanced and Recurrent Gastric Cancer
- S-1 failure for Patients with Advanced and Recurrent Gastric Cancer
- The Tokyo cooperative oncology group
- 2008-04-01
Other
- A study to investigate the safety, pharmacokinetics, occurrence of anti-drug antibody, and anti-RSV neutralizing antibody following 2 doses administration of nirsevimab (MEDI8897) in infants with certain health conditions or born pre-term in Japan
- RSV invection
- jRCT Inquiries IQVIA contact person
- 2023-07-26
Recruiting
- Effect on Brain Function by Immobilization after Arthroscopic Rotator Cuff Repair
- Rotator cuff tear
- Shitara Hitoshi
- 2021-12-10
Recruiting
- G-CSF for Promotion of Rotator Cuff Healing
- Rotator cuff tear
- Shitara Hitoshi
- 2022-05-30
Other
- Discontinuation of infliximab therapy after acquisition of low disease activity by infliximab in rheumatoid arthritis study: RRR (remission induction by remicade) study
- rheumatoid arthritis
- University of Occupational & Environmental Health, Japan
- 2009-06-23
Other
- Safety of Biologics in Clinical Use in Japanese Patients with Rheumatoid Arthritis in Long-Term (SECURE)
- Rheumatoid Arthritis
- Japan College of Rheumatology
- 2008-09-01
Recruiting
- CIDEX
- Residual hearing in low frequencies and severe to profound sensorineural hearing loss in high freque
- Usami Shin-ichi
- 2023-12-21
Other
- Randomiszd phase III trial of adjuvant chemotherapy with gemcitabine vs. S-1 in patients with resected pancreatic cancer
- Resected pancreatic cancer
- Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)
- 2007-04-01
Other
- Multi-Center Phase II Study on Efficacy of High-Slip Skin Care Pad for Hand-Foot Skin Reaction Caused by Sorafenib in Patients with Renal Cell Carcinoma
- Renal cell carcinoma
- Japanese Society of Renal Cancer (JSRC)
- 2009-05-29
Other
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
- relapsed/refractory multiple myeloma
- Kawai Norisuke
- 2021-08-06